RecruitingNot ApplicableNCT07801235

HYperfractionated Radiation Therapy Versus Concurrent Chemoradiation for Head and Neck Cancer (HYTC)

HYperfractionated Radiation Therapy Versus Concurrent Chemoradiation for Head and Neck Cancer (HYTC): A Phase III Randomized Controlled Trial

Sponsor

King Hussein Cancer Center

Enrollment

604 participants

Start Date

Aug 20, 2026

Study Type

INTERVENTIONAL

Conditions

Head and Neck (HNSCC)

Summary

This is an international multi-centre, non-inferiority phase III randomized controlled trial comparing concurrent chemoradiation with high dose cisplatin (Arm A) vs. hyperfractionated radiation therapy (Arm B) in patients with head and neck squamous cell carcinoma.

Eligibility

Min Age: 18 YearsMax Age: 75 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying 70 gy 35 fractions/7weeks+high dose of cisplatin and 81.6 Gy /68 fractions BID FOR 7 WEEKS for people with head and neck (hnscc). The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years to 75 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.